Meeting
2022 ASCO Annual Meeting
Prognostic implications of HER2Neu-low in metastatic breast cancer.
Authors
Shaakir Hasan
New York Proton Center, New York, NY
Shaakir Hasan , Zachary Neubauer , Robert H. Press , Arpit Chhabra , Jana Lauren Fox , Oren Cahlon , Richard Lorne Bakst , Charles B. Simone II, J. Isabelle Choi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1044)
DOI
10.1200/JCO.2022.40.16_suppl.1044
Abstract #
1044
Poster Bd #
422
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The contribution of clinical subtype to survival differences among patients with de novo and recurrent metastatic breast cancer (dMBC).
First Author: Danielle Marie File
Poster
2023 ASCO Annual Meeting
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
First Author: Rinath Jeselsohn
Poster
2023 ASCO Annual Meeting
Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.
First Author: Kewei Sylvia Shi
Poster
2023 ASCO Annual Meeting
Breast cancer staging for patients with “low risk” disease: Are they all the same?
First Author: Jennifer Kay Plichta